Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #CSEStocks #OTC #OTCMarkets #OTCStocks #SmallCaps #Investing
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer. The vaccine was shown to be therapeutically effective against pre-established pancreatic...
http://dlvr.it/T6FtKT
http://dlvr.it/T6FtKT
Comments
Post a Comment